🇺🇸

Regulatory Compliance

· daily

US SEC Trading Suspension Halt Orders — April 30, 2026

Across four 8-K filings in the USA Trading Suspensions stream, small-cap Nasdaq-listed companies face mounting compliance pressures, with 3/4 (Elite Express, Stardust Power, American Resources) receiving deficiency notices for bid price, market value/listed securities (MVLS), equity/net income, and late 10-K filing, but all granted cure periods extending to October 2026 with no immediate trading halts or delistings. Innventure stands out positively with board refresh appointing operations and finance experts amid shareholder engagement, contrasting sector governance strains. No period-over-period financial trends (YoY/QoQ revenue, margins) or insider trading activity reported across filings, limiting quantitative growth insights, though forward-looking compliance deadlines create a catalyst calendar clustered in Q3/Q4 2026. Capital allocation details absent, but operational highlights like Stardust's Lithium Refinery Project support signal potential turnaround paths. Portfolio-level pattern: emerging growth companies vulnerable to Nasdaq rules 5550/5250, implying heightened delisting risk and volatility; investors should prioritize monitoring for cure success amid mixed/negative sentiment (avg materiality 8.25/10). Market implications include short-term trading stability but elevated long-term suspension risks, favoring defensive positioning.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — April 29, 2026

Four small-cap companies on Nasdaq Capital Market (SGMO, IVF, VSTD, RVYL) disclosed critical compliance failures on April 23-28, 2026, triggering trading suspension risks and delisting threats under Nasdaq rules. Common themes include bid price deficiencies (SGMO), untimely 10-K/10-Q filings due to restatements (IVF, VSTD), and stockholders' equity shortfalls (RVYL), with no enriched period-over-period financial trends available indicating underlying operational weaknesses rather than growth. SGMO faces imminent suspension on May 5, 2026, shifting to OTCQB, while others pursue appeals or compliance plans amid mixed resolutions like RYVYL's $20M+ merger boost. Market implications: heightened volatility, liquidity erosion, and short-term trading halts for microcaps, signaling broader small-cap distress without positive YoY/QoQ revenue or margin expansions. Portfolio-level pattern: 100% of filings show regulatory halts tied to prolonged non-compliance (e.g., SGMO's two failed periods ending Oct 2025/Apr 2026), urging avoidance of longs in similar profiles.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — April 28, 2026

A cluster of 6 Nasdaq-related 8-K filings on April 28, 2026, highlights ongoing minimum bid price compliance challenges for small-cap US-listed companies, with trading suspension and delisting risks in focus. Giftify Inc. and NextPlat Corp. stand out positively, both regaining compliance on April 27, 2026, after meeting the $1 bid price for 10 consecutive days, closing their respective 180-day grace periods without delisting—marking bullish resolutions amid high materiality (8/10). In contrast, four new filings (Arrive AI, Citius Oncology, Vivakor, GridAI) disclose delisting notices under similar rules, though rated low risk (materiality 5/10) with no immediate halts. No period-over-period financial trends (e.g., YoY revenue/margins) or insider trading activity reported across filings; forward-looking compliance periods average 180 days from notice dates. Portfolio-level pattern: 2/6 companies (33%) achieved quick turnarounds within 1-12 months, suggesting potential for rapid rebounds in microcaps; AI and biotech sectors overrepresented in notices. Implications: Reduced suspension risk for compliant firms boosts liquidity; monitor others for volatility and catalyst-driven bids.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — April 27, 2026

In the USA Trading Suspensions stream, two Nasdaq-listed small caps show divergent compliance trajectories: Greenlane Holdings (GNLN) resolved its minimum bid price deficiency in under a month, averting a May 5, 2026 delisting hearing, while Gulf Resources (GURE) received a fresh notice for delayed 10-K filing, risking delisting proceedings. No direct period-over-period financial trends available, but Greenlane's rapid compliance regain (from March 25 notice to April 21 resolution) contrasts sharply with Gulf's ongoing filing delay for FY 2025 ended Dec 31, 2025. Board-affiliated warrant holders at Greenlane locked up 162,760 warrants until April 23, 2027, signaling conviction amid resolved risk. Gulf faces a 60-day compliance plan deadline (~June 22, 2026) with potential extension to October 12, 2026. Overarching theme: Heightened Nasdaq scrutiny on small-cap governance and reporting, with positive resolution in bid price issues but persistent late-filing risks. Market implications include potential relief rally for GNLN and downside pressure on GURE, highlighting portfolio-level vigilance on delisting catalysts in micro-caps.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — April 24, 2026

Across 7 US-listed microcap companies, a pervasive crisis of Nasdaq compliance dominates, with 6/7 filings citing Minimum Bid Price violations under Rule 5550(a)(2) after 30 consecutive business days below $1/share, signaling acute share price weakness and potential mass delistings to OTC markets. Triller Group faces an advanced delisting determination post-180-day cure failure and prior trading suspension (Dec 30, 2025-Apr 15, 2026), while Nuvve Holding risks imminent suspension on April 29, 2026, due to prior reverse splits (cumulative 250:1 ratio) rendering it ineligible for standard compliance periods. Mannatech stands out as the sole equity deficiency case ($5.223M deficit vs $2.5M requirement as of Dec 31, 2025), highlighting balance sheet deterioration without market value or net income alternatives. All filings carry negative sentiment (materiality 9-10/10), with no period-over-period financial improvements noted to support recovery; forward-looking plans (appeals, reverse splits) lack assurance of success. Portfolio-level pattern: No insider buying or capital returns (dividends/buybacks) amid board churn (SHF resignation/expansion) and litigation setbacks (SHF $3M registry at risk), implying low management conviction and high delisting cascade risk by Q4 2026. Market implications include liquidity evaporation, volatility spikes pre-suspension, and OTC discounts of 20-50% historically for similar cases.

7 high priority 7 total filings
· daily

US SEC Trading Suspension Halt Orders — April 23, 2026

A cluster of 9 small-cap companies across diverse sectors faced Nasdaq and NYSE American listing compliance issues in mid-April 2026, with 4/9 citing delayed 10-K filings for FY ended Dec 31, 2025, 3/9 low bid prices, and 2/9 stockholders' equity shortfalls below $2.5M thresholds. Sentiments are predominantly negative (7/9), signaling broad micro-cap distress with delisting risks threatening liquidity, financing, and operations; no immediate trading suspensions except Triller's prior halt resolved post-10-K filing. Key trends include persistent FY2025 weaknesses (e.g., Boxlight equity at $1.255M vs $2.5M req, 50% shortfall), with mixed positives in VolitionRx's plan acceptance (extension to Aug 6, 2027) and SmartKem's equity compliance regain (but bid price monitor to Sep 1, 2026). Portfolio-level pattern: 8/9 lack financial health assurances, amplifying sector-wide volatility; Mawson's name change to Big Digital Energy amid notice adds rebranding risk. Implications: Heightened short opportunities and avoidance for long portfolios, with catalyst calendar clustered in June-Oct 2026 for compliance plans.

9 high priority 9 total filings
· daily

US SEC Trading Suspension Halt Orders — April 22, 2026

A surge of 8 small-cap companies across energy, biotech/pharma, technology, and real estate sectors received noncompliance notices from NYSE American (3) and Nasdaq (5) between April 16-20, 2026, primarily for failing to file 10-Ks for FY ended Dec 31, 2025, signaling systemic audit delays and financial reporting weaknesses among micro-caps. 7/8 filings cite late 10-Ks (Form 12b-25 filed March/April 2026), with one (Tevogen) failing market value rules ($50M MVLS, $15M MVPHS) and Vivos reporting negative equity of -$1.55M despite Q1 2026 $6.8M raise ($4.6M warrants + $2.25M placement). Sentiments are negative across 7/8 (mixed for Vivos), all 9/10 materiality, with cure periods clustered around October 12-15, 2026, after initial 60-180 day plans. No YoY/QoQ financial trends or insider activity reported, but operational highlights include EON's 1,000+ bopd from 750 Permian wells and La Rosa's Europe expansion. Delisting risks loom without assurances of compliance, pressuring listings and liquidity; Apimeds faces active trading halt since April 2. Portfolio implication: Avoid longs in these tickers, watch for suspensions amplifying volatility.

8 high priority 8 total filings
· daily

US SEC Trading Suspension Halt Orders — April 21, 2026

Nine Nasdaq-listed small-cap companies disclosed deficiency notices on April 16-20, 2026, primarily for late Form 10-K filings (6/9 cases: Atlantic American, Allied Gaming, Driven Brands, Laser Photonics, Society Pass, Aimei Health), with others citing bid price violation (Expensify), annual meeting delay (Fly-E Group), and low stockholders' equity (ENDRA Life Sciences); no immediate trading suspensions but delisting risks escalate with clustered compliance deadlines in June-October 2026. Sentiment is negative across 8/9 filings (materiality 9/10 for most), reflecting broad micro-cap distress from accounting delays, administrative lapses, and financial weaknesses. Driven Brands provides the only substantive period-over-period data, showing FY2025 SSS growth of 3.5%-3.7% (Driven) and 6.1%-6.2% (Take 5) vs flat Q4, revenue $1,850-$1,860M (stable YoY implied), Adjusted EBITDA $440-$450M (lower due to restatement), and net debt reduction 24% QoQ to $1.6B with net unit growth of 175 FY2025/29 Q1 2026. Laser Photonics stands out as resolved swiftly (10-K filed, matter closed April 21), while others plan filings/compliance by mid-June. Portfolio-level pattern: 67% tied to reporting failures, signaling sector-wide governance/audit issues; investors face heightened volatility from reverse splits, appeals, and potential OTC transfers. Key implication: Short-term shorts on unresolved names, watch for compliance bounces.

9 high priority 9 total filings
· daily

US SEC Trading Suspension Halt Orders — April 20, 2026

A wave of regulatory non-compliance notices hit 6 US-listed companies on April 14-17, 2026, primarily from Nasdaq and NYSE, signaling acute distress among small-cap and emerging growth firms with trading suspensions, delistings, and delisting risks imminent. Key themes include bankruptcy-driven delistings (QVC Group and QVC Inc.), deficient stockholders' equity (Nocera at -$(440k) vs $2.5M req.), low MVPHS (Armlogi below $5M for 30 days), low bid prices (OneMedNet < $1 for 30 days), and late 10-K filings (IT Tech), with no period-over-period financial improvements noted and all sentiments negative at materiality 9-10/10. No YoY/QoQ revenue growth, margin expansions, or positive insider activity observed across filings; instead, forward-looking plans lack assurance of compliance regain. Market implications: portfolio-level pressure on Nasdaq Capital/Global Market and NYSE American listings, equity wipeouts in bankruptcies, speculative OTC trading post-delist. Emerging growth companies (Armlogi, Nocera) overrepresented, highlighting vulnerability in low-liquidity names amid 2026 market volatility.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — April 17, 2026

All five companies in this USA Trading Suspensions stream faced Nasdaq deficiency notices between April 15-17, 2026, signaling acute listing compliance risks with uniformly negative sentiment (100% negative across filings) and high materiality (9/10 average). Three firms (MBIO, ALBT, VRME) violated Rule 5550(a)(2) due to common stock closing below $1.00 for 30 consecutive business days (March 1-April 14/17 periods), while two (GITS, NKLR) breached Rule 5250(c)(1) via untimely 10-K filings for FY ended Dec 31, 2025. No immediate trading halts occurred, with grace periods extending to June 15 (compliance plans) and October 12-14, 2026 (full compliance), but failure risks delisting, appeals, or reverse splits. Absent enriched period-over-period financial trends or insider activity, the cluster highlights microcap distress patterns, potentially signaling broader small-cap liquidity/operational challenges amid no reported YoY revenue/margin data. Portfolio implication: elevated volatility and downside bias near catalyst dates, with 60-180 day windows for remediation but low success odds without capital raises.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — April 16, 2026

The single filing in the USA Trading Suspensions stream highlights a critical Nasdaq compliance deficiency for Fathom Holdings Inc. (FTHM), with its bid price below $1.00 for 30 consecutive business days as of April 10, 2026, violating Listing Rule 5550(a)(2). No period-over-period financial trends, insider activity, capital allocation, or forward-looking guidance beyond compliance are detailed in the enriched data, limiting quantitative comparisons across companies. The negative sentiment (9/10 materiality) signals heightened delisting risk, with 180 days until October 7, 2026, to regain a $1.00+ bid for 10 consecutive days under Rule 5810(c)(3)(A). Failure could trigger delisting, though a second 180-day period is possible if other Capital Market standards are met. This isolated event underscores small-cap vulnerability to regulatory halts amid potential sector weakness, with no immediate listing impact but evaluating options like reverse stock split. Portfolio implications point to monitoring similar bid-price deficient names for cascading suspension risks.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — April 15, 2026

Three small-cap companies—Soluna Holdings (SLNH), Alaunos Therapeutics, and BioCardia (BCDA)—disclosed Nasdaq non-compliance notices between April 9-10, 2026, highlighting acute financial distress with negative sentiment across all filings (materiality 9/10). Soluna faces bid price deficiency below $1.00 for 30 consecutive days under Rule 5550(a)(2), while Alaunos and BioCardia report critically low stockholders' equity ($2.153M and $895K respectively vs. $2.5M minimum under Rule 5550(b)(1)), with BioCardia's level representing only 36% of requirement (worst outlier). No enriched period-over-period trends (YoY/QoQ revenue, margins) or insider activity provided, implying persistent deterioration without management support via buys. Forward-looking compliance deadlines offer narrow paths to avoidance: SLNH has 180 days to October 7, 2026, for price cure; others must submit plans by May 25-26, 2026, for potential 180-day extensions. Common portfolio-level pattern: small-cap vulnerability to Nasdaq standards, bearish for share prices with delisting risks amplifying volatility. No capital allocation (dividends/buybacks) or M&A activity noted, underscoring cash constraints. Trading continues unaffected now, but failures could trigger OTC delistings and sharp declines.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — April 14, 2026

The single filing in the USA Trading Suspensions stream reveals acute delisting risk for Beasley Broadcast Group, Inc. (BBGI), which received a Nasdaq deficiency notice on April 13, 2026, for failing the $2,500,000 minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), reporting a $49,330,431 deficit in its December 31, 2025 Form 10-K. No period-over-period financial trends are detailed, but the deficit underscores severe balance sheet deterioration with no alternative listing standards met. Forward-looking risks emphasize no assurance of compliance plan approval by May 28, 2026, or extension to October 10, 2026, potentially leading to trading halt or delisting. Negative sentiment (10/10 materiality) dominates, signaling high portfolio risk for media/broadcast exposure. Investors face immediate implications for liquidity and valuation in suspension-prone small-caps, with ongoing trading under BBGI but elevated downside.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — April 13, 2026

Two small-cap companies, VEEA Inc. and Twin Vee PowerCats (VEEE), disclosed critical Nasdaq listing compliance failures in their April 2026 8-K filings, highlighting a portfolio-level theme of micro-cap distress amid prolonged bid price and market value deficiencies. VEEA failed Minimum Bid Price ($1.00), MVPHS ($15M), and MVLS ($50M) requirements by the March 30, 2026 deadline but secured a transfer to Nasdaq Capital Market (effective April 9, 2026) and a second 180-day extension to September 28, 2026, yielding mixed sentiment; VEEE received a delisting notice with no remediation path disclosed, paired with dilutive share authorization increases, driving negative sentiment. No period-over-period financial trends, revenue growth, or margin data were reported, but compliance failures imply QoQ/YOY deterioration in stock price (below $1 for VEEA since Sept 2025) and market cap metrics. Capital allocation shows VEEE pursuing defensive governance (classified board, 60% removal threshold) and massive share authorization (500M common shares), signaling entrenchment amid distress. Market implications include heightened delisting risks, potential reverse splits, and trading halts, creating short opportunities while VEEA's extension offers limited near-term stability. Overall, 2/2 filings exhibit high materiality (9/10), underscoring regulatory pressure on Nasdaq micro-caps with no bullish portfolio trends evident.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — April 10, 2026

A cluster of six Nasdaq-listed microcap companies received deficiency notices on April 7, 2026, primarily for failing the $1.00 minimum bid price requirement over 30 consecutive business days (Feb 23-Apr 6, 2026) or stockholders' equity below $2.5M as of Dec 31, 2025, signaling acute delisting risks across emerging growth firms. Four filings highlight bid price non-compliance, with three ineligible for standard 180-day extensions due to prior reverse stock splits (DevvStream, Beyond Air, SCWorx), while two face equity shortfalls (Caring Brands at $2.09M vs $2.5M req., Callan JMB below $2.5M). No positive period-over-period financial trends evident; persistent sub-$1 bids reflect YoY/QoQ share price deterioration amid weak fundamentals. SCWorx faces imminent trading suspension on April 14 post failed 180-day extension from 2025 notice. Portfolio implications include heightened volatility, potential OTC delistings, and liquidity evaporation for small-cap holders; no bullish insider activity or capital returns noted, all sentiments negative with high materiality (9-10/10).

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — April 09, 2026

A cluster of 5 Nasdaq-related regulatory actions highlights acute distress among small-cap US-listed companies, with Actelis Networks facing immediate delisting on April 10, 2026, after a failed 1-for-10 reverse split on November 18, 2025, marking the most severe outcome. Three companies (Gossamer Bio, FibroGen, Newton Golf) received deficiency notices for bid price, assets/revenue, and stockholders' equity failures, respectively, with 45-180 day compliance windows through October 2026, while Beyond Meat resolved a late 10-K filing without disruption. No enriched period-over-period financial trends show growth; instead, implied YoY deteriorations (e.g., FibroGen revenue shifted to discontinued ops for 2024-2025) underscore weak fundamentals driving non-compliance. Biotech firms (Gossamer, FibroGen) represent 40% of cases, signaling sector-specific pressures amid low bid prices and asset shortfalls. Portfolio-level implications include liquidity erosion, OTC transitions, and heightened short opportunities, with no bullish capital allocation or insider buying patterns evident across filings.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — April 08, 2026

The USA Trading Suspensions stream features one key filing from SPAR Group, Inc. (SGRP), highlighting acute Nasdaq compliance failure with stockholders’ equity at just $622,000 as of December 31, 2025, versus the required $2.5 million minimum, alongside failures in alternative criteria of $35 million market value or $500,000 net income. No period-over-period comparisons available in the filing, but the equity deficiency signals ongoing financial deterioration into YE 2025 from prior 10-K data. This represents a 10/10 materiality event with negative sentiment, posing immediate delisting risk on Nasdaq Capital Market. Portfolio-level trends are limited to this single instance in a very quiet session, but it underscores small-cap vulnerability to regulatory halts. Market implications include potential trading suspension, heightened volatility, and forced liquidation pressures for holders. No bullish offsets from insider activity, capital allocation, or forward guidance noted.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — April 07, 2026

Across five small-cap filings in the USA Trading Suspensions stream, a dominant theme is Nasdaq non-compliance with Listing Rule 5550(b)(1) due to severe stockholders’ equity deficits (HYFM -$63.3M, Direct Digital -$7.0M as of Dec 31, 2025), alongside bid price issues (Tianci resolved), NYSE filing delays (Genie), and voluntary delisting (WM Technology). Negative sentiment prevails in 4/5 cases (materiality 9-10/10), signaling heightened delisting risks and potential trading halts, with no period-over-period financial improvements noted to reverse deficits QoQ into Q1 2026. Forward-looking catalysts cluster in April-May 2026, including compliance plans (HYFM May 16), hearings (Direct Digital by Apr 9), and delisting (WM ~Apr 24), implying immediate liquidity erosion on US exchanges. No insider trading activity reported across filings, but persistent deficits vs required $2.5M minimum highlight capital allocation failures and operational distress. Portfolio-level pattern: 80% of companies face imminent regulatory cliffs, favoring short/avoid strategies for Nasdaq small caps amid no YoY equity recovery trends.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — April 03, 2026

A cluster of five micro-cap companies across tech, AI, biotech, and marine sectors received delisting deficiency notices from Nasdaq and NYSE American between March 31 and April 2, 2026, signaling acute listing compliance pressures amid sustained low bid prices, equity shortfalls, and market value deficiencies. Common themes include bid price failures below $1 for 30 consecutive business days (e.g., Twin Vee post-1-for-10 reverse split in April 2025), stockholders' equity deficits (Matinas at $4.83M below $2M-$6M thresholds with 5-year losses; AEON at -$55M deficit with losses in 3/4 years), and MVPHS/MVLS shortfalls (Arrive AI below $15M/$50M). No positive period-over-period financial trends evident; instead, prolonged deficiencies (e.g., Aeries initial notice September 2025) indicate deteriorating compliance trajectories with no YoY equity recovery or bid price stabilization. All firms plan appeals or compliance plans, but ineligibility for extensions (e.g., Twin Vee, Aeries) heightens delisting risks, potentially leading to trading halts, OTC transfers, and shareholder value erosion. Portfolio-level pattern: 5/5 companies show negative sentiment (4/5 outright negative, 1 mixed), with biotechs overrepresented in equity failures; investors face liquidity risks in small caps. Critical implication: Imminent catalyst calendar of hearings and plans could trigger suspensions, advising avoidance or short positioning.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — April 02, 2026

Across five US-listed small-cap companies, a cluster of Nasdaq and NYSE listing compliance failures emerged in late March-early April 2026, primarily driven by sub-$1.00 bid prices (3/5 filings), low market value of listed securities (1/5), governance issues (1/5), and insufficient market cap (1/5), signaling broad small-cap distress amid low valuations. No period-over-period financial trends like revenue growth or margins are detailed, but prior non-compliance periods (e.g., CytoSorbents' initial 180 days ending March 31, 2026) highlight persistent deterioration in stock price and market value metrics over 30-180 day windows. Most receive 180-day compliance extensions to September 2026 with no immediate delisting, except Solo Brands facing NYSE delisting proceedings starting April 2, 2026, and OTC transition. Sentiments skew negative/mixed (3 negative, 2 mixed), with high materiality (avg 9/10), implying elevated delisting risks, potential reverse splits, and liquidity erosion. Portfolio-level pattern: 4/5 emerging growth companies, concentrated Nasdaq issues (80%), pointing to sector-wide undervaluation or operational challenges in biotech/tech/consumer spaces. Market implications include heightened volatility, OTC trading discounts, and short-term trading opportunities around appeals/compliance catalysts.

5 high priority 5 total filings